Debate Round 2: Managing Luspatercept Super Responders (Dose Reduce vs Hold Dose)

Debate Round 2: Managing Luspatercept Super Responders (Dose Reduce vs Hold Dose)

Panelists discuss how to manage luspatercept “super responders” with hemoglobin levels above 12 g/dL, with Team Whataburger advocating for dose reduction to maintain stable responses and avoid hemoglobin fluctuations that disrupt patients’ quality of life, while Team In-and-Out argues for holding doses due to lack of safety data at very high hemoglobin levels and cost considerations. However, both teams acknowledge the need for individualized ap…